Hydroxyapatite Nanoparticles for Improved Cancer Theranostics

Overview

Journal J Funct Biomater

Specialty Biomedical Engineering

Date 2022 Jul 27

PMID 35893468

Authors

Saeid Kargozar

Sahar Mollazadeh

Farzad Kermani

Thomas J Webster

Simin Nazarnezhad

Sepideh Hamzehlou

Francesco Baino

Affiliations

Soon will be listed here.

Abstract

Beyond their well-known applications in bone tissue engineering, hydroxyapatite nanoparticles (HAp NPs) have also been showing great promise for improved cancer therapy. The chemical structure of HAp NPs offers excellent possibilities for loading and delivering a broad range of anticancer drugs in a sustained, prolonged, and targeted manner and thus eliciting lower complications than conventional chemotherapeutic strategies. The incorporation of specific therapeutic elements into the basic composition of HAp NPs is another approach, alone or synergistically with drug release, to provide advanced anticancer effects such as the capability to inhibit the growth and metastasis of cancer cells through activating specific cell signaling pathways. HAp NPs can be easily converted to smart anticancer agents by applying different surface modification treatments to facilitate the targeting and killing of cancer cells without significant adverse effects on normal healthy cells. The applications in cancer diagnosis for magnetic and nuclear in vivo imaging are also promising as the detection of solid tumor cells is now achievable by utilizing superparamagnetic HAp NPs. The ongoing research emphasizes the use of HAp NPs in fabricating three-dimensional scaffolds for the treatment of cancerous tissues or organs, promoting the regeneration of healthy tissue after cancer detection and removal. This review provides a summary of HAp NP applications in cancer theranostics, highlighting the current limitations and the challenges ahead for this field to open new avenues for research.

Citing Articles

Drug Repurposing and Nanotechnology for Topical Skin Cancer Treatment: Redirecting toward Targeted and Synergistic Antitumor Effects.

Martins M, Veiga F, Paiva-Santos A, Pires P ACS Pharmacol Transl Sci. 2025; 8(2):308-338.

PMID: 39974652 PMC: 11833728. DOI: 10.1021/acsptsci.4c00679.

Application of Hydroxyapatite Obtained by Different Techniques: Metabolism and Microarchitecture Characteristics (Review).

Markelov V, Danilko K, Solntsev V, Pyatnitskaya S, Bilyalov A Sovrem Tekhnologii Med. 2025; 16(6):60-75.

PMID: 39896152 PMC: 11780588. DOI: 10.17691/stm2024.16.6.06.

Advancements in nanohydroxyapatite: synthesis, biomedical applications and composite developments.

Zhao R, Meng X, Pan Z, Li Y, Qian H, Zhu X Regen Biomater. 2025; 12:rbae129.

PMID: 39776858 PMC: 11703556. DOI: 10.1093/rb/rbae129.

3D Bioprinting in Limb Salvage Surgery.

Timofticiuc I, Dragosloveanu S, Caruntu A, Scheau A, Badarau I, Dragos Garofil N J Funct Biomater. 2024; 15(12).

PMID: 39728183 PMC: 11677104. DOI: 10.3390/jfb15120383.

Anti-Cancer Activities of Nano Amorphous Calcium Phosphates toward Premalignant and Oral Cancer Cells.

Herendija E, Jaksic Karisik M, Milasin J, Lazarevic M, Ignjatovic N Biomedicines. 2024; 12(7).

PMID: 39062071 PMC: 11274579. DOI: 10.3390/biomedicines12071499.

References

Wang R, Liu W, Wang Q, Li G, Wan B, Sun Y . Anti-osteosarcoma effect of hydroxyapatite nanoparticles both in vitro and in vivo by downregulating the FAK/PI3K/Akt signaling pathway. Biomater Sci. 2020; 8(16):4426-4437. DOI: 10.1039/d0bm00898b. View

Kostka L, Kotrchova L, Subr V, Libanska A, Ferreira C, Malatova I . HPMA-based star polymer biomaterials with tuneable structure and biodegradability tailored for advanced drug delivery to solid tumours. Biomaterials. 2020; 235:119728. PMC: 7123463. DOI: 10.1016/j.biomaterials.2019.119728. View

Ansari L, Derakhshi M, Bagheri E, Shahtahmassebi N, Malaekeh-Nikouei B . Folate conjugation improved uptake and targeting of porous hydroxyapatite nanoparticles containing epirubicin to cancer cells. Pharm Dev Technol. 2020; 25(5):601-609. DOI: 10.1080/10837450.2020.1725045. View

Wang C, Ye Y, Hu Q, Bellotti A, Gu Z . Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. Adv Mater. 2017; 29(29). DOI: 10.1002/adma.201606036. View

Beik J, Abed Z, Ghoreishi F, Hosseini-Nami S, Mehrzadi S, Shakeri-Zadeh A . Nanotechnology in hyperthermia cancer therapy: From fundamental principles to advanced applications. J Control Release. 2016; 235:205-221. DOI: 10.1016/j.jconrel.2016.05.062. View

Han Y, Li S, Cao X, Yuan L, Wang Y, Yin Y . Different inhibitory effect and mechanism of hydroxyapatite nanoparticles on normal cells and cancer cells in vitro and in vivo. Sci Rep. 2014; 4:7134. PMC: 4238015. DOI: 10.1038/srep07134. View

Zheng X, Liu M, Hui J, Fan D, Ma H, Zhang X . Ln(3+)-doped hydroxyapatite nanocrystals: controllable synthesis and cell imaging. Phys Chem Chem Phys. 2015; 17(31):20301-7. DOI: 10.1039/c5cp01845e. View

Tornin J, Villasante A, Sole-Marti X, Ginebra M, Canal C . Osteosarcoma tissue-engineered model challenges oxidative stress therapy revealing promoted cancer stem cell properties. Free Radic Biol Med. 2021; 164:107-118. PMC: 7921834. DOI: 10.1016/j.freeradbiomed.2020.12.437. View

Yanhua W, Hao H, Li Y, Zhang S . Selenium-substituted hydroxyapatite nanoparticles and their in vivo antitumor effect on hepatocellular carcinoma. Colloids Surf B Biointerfaces. 2016; 140:297-306. DOI: 10.1016/j.colsurfb.2015.12.056. View

10.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

11.

Chen F, Huang P, Zhu Y, Wu J, Zhang C, Cui D . The photoluminescence, drug delivery and imaging properties of multifunctional Eu3+/Gd3+ dual-doped hydroxyapatite nanorods. Biomaterials. 2011; 32(34):9031-9. DOI: 10.1016/j.biomaterials.2011.08.032. View

12.

Khan S, Ullah M, Siddique R, Liu Y, Ullah I, Xue M . Catechins-Modified Selenium-Doped Hydroxyapatite Nanomaterials for Improved Osteosarcoma Therapy Through Generation of Reactive Oxygen Species. Front Oncol. 2019; 9:499. PMC: 6585473. DOI: 10.3389/fonc.2019.00499. View

13.

Kermani F, Mollazadeh S, Kargozar S, Vahdati Khakhi J . Improved osteogenesis and angiogenesis of theranostic ions doped calcium phosphates (CaPs) by a simple surface treatment process: A state-of-the-art study. Mater Sci Eng C Mater Biol Appl. 2021; 124:112082. DOI: 10.1016/j.msec.2021.112082. View

14.

Govindan B, Swarna Latha B, Nagamony P, Ahmed F, Saifi M, Harrath A . Designed Synthesis of Nanostructured Magnetic Hydroxyapatite Based Drug Nanocarrier for Anti-Cancer Drug Delivery toward the Treatment of Human Epidermoid Carcinoma. Nanomaterials (Basel). 2017; 7(6). PMC: 5485785. DOI: 10.3390/nano7060138. View

15.

Fass L . Imaging and cancer: a review. Mol Oncol. 2009; 2(2):115-52. PMC: 5527766. DOI: 10.1016/j.molonc.2008.04.001. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Simon A, Dutta D, Chattopadhyay A, Ghosh S . Quercetin-Loaded Luminescent Hydroxyapatite Nanoparticles for Theranostic Application in Monolayer and Spheroid Cultures of Cervical Cancer Cell Line . ACS Appl Bio Mater. 2022; 4(5):4495-4506. DOI: 10.1021/acsabm.1c00255. View

18.

Dolmans D, Fukumura D, Jain R . Photodynamic therapy for cancer. Nat Rev Cancer. 2003; 3(5):380-7. DOI: 10.1038/nrc1071. View

19.

Kermani F, Mollazadeh S, Kargozar S, Vahdati Khakhi J . Solution combustion synthesis (SCS) of theranostic ions doped biphasic calcium phosphates; kinetic of ions release in simulated body fluid (SBF) and reactive oxygen species (ROS) generation. Mater Sci Eng C Mater Biol Appl. 2020; 118:111533. DOI: 10.1016/j.msec.2020.111533. View

20.

Cheung A, Bax H, Josephs D, Ilieva K, Pellizzari G, Opzoomer J . Targeting folate receptor alpha for cancer treatment. Oncotarget. 2016; 7(32):52553-52574. PMC: 5239573. DOI: 10.18632/oncotarget.9651. View